Advertisement

Psychopharmacology

, Volume 181, Issue 1, pp 170–178 | Cite as

Dronabinol and marijuana in HIV+ marijuana smokers: acute effects on caloric intake and mood

  • Margaret Haney
  • Judith Rabkin
  • Erik Gunderson
  • Richard W. Foltin
Original Investigation

Abstract

Rationale

No studies to date have directly compared the tolerability and efficacy of smoked marijuana and oral dronabinol in HIV+ marijuana smokers.

Objectives

The aim of this study was to compare dronabinol (0, 10, 20, 30 mg p.o.) and marijuana [0.0, 1.8, 2.8, 3.9% Δ9-tetrahydrocannabinol (THC)] in two samples of HIV+ marijuana smokers: those with (n=15) and those without (n=15) a clinically significant loss of muscle mass (<90% body cell mass/height), which is one component of AIDS wasting.

Methods

Mood, physical symptoms, self-selected food intake, cardiovascular data, and cognitive task performance were measured before and repeatedly after dronabinol and marijuana administration in eight 7-h sessions. Marijuana and dronabinol were administered in randomized order using a within-subject, staggered, double-dummy design.

Results

As compared to placebo, (1) marijuana (1.8, 2.8, 3.9% THC) and the lower dronabinol doses (10, 20 mg) were well tolerated (e.g., few physical symptoms, significant increases in ratings of “good drug effect”) in both groups of participants; the highest dose of dronabinol (30 mg) was poorly tolerated in a subset of participants; (2) marijuana and dronabinol significantly increased caloric intake in the low bioelectrical impedance analysis (BIA) group but not in the normal BIA group; and (3) drug effects on cognitive performance were minor.

Conclusions

These data suggest that for experienced marijuana smokers with clinically significant muscle mass loss, both dronabinol (at acute doses at least four to eight times the current recommendation) and marijuana produce substantial and comparable increases in food intake without producing adverse effects.

Keywords

Cannabinoids AIDS THC Appetite 

Notes

Acknowledgements

We are grateful to Mabel Torres, Stephanie Wexelbaum, Cassidy Cleavinger, Martin McElhiney, Ph.D., Judy Chiu, and Carl Hart, Ph.D., for their excellent assistance in completing this research. We also thank the US National Institute on Drug Abuse and the National Center for Complementary and Alternative Medicine (DA 09236 and DA12698) for their support and for providing study marijuana.

References

  1. Abrams DI (2000) Potential interventions for HIV/AIDS wasting: an overview. J Acquir Immune Defic Syndr 25:S74–S80CrossRefPubMedGoogle Scholar
  2. Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune JM, Schambelan M (2003) Short-term effects of cannabinoids in patients with HIV-1 infection. Ann Intern Med 139:258–266PubMedGoogle Scholar
  3. Agurell S, Halldin M, Lindfren J, Ohlsson A, Widman M, Gillespie H, Hollister L (1986) Pharmacokinetics and metabolism of Δ1 tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 38:21–43PubMedGoogle Scholar
  4. Beal JE, Olson R, Laubenstein L, Morales JO, Bellman P, Yangco B, Lefkowitz L, Plasse TF, Shepard KV (1995) Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 10:89–97CrossRefPubMedGoogle Scholar
  5. Beal JE, Olson R, Lefkowitz L, Laubenstein L, Bellman P, Yangco B, Morales JO, Murphy R, Powderly W, Plasse TF, Mosdell KW, Shepard KV (1997) Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 14:7–14PubMedCrossRefGoogle Scholar
  6. Calhoun SR, Galloway GP, Smith DE (1998) Abuse potential of dronabinal (Marinol). J Psychoactive Drugs 30:187–196PubMedGoogle Scholar
  7. Chait LD, Pierri J (1989) Some physical characteristics of NIDA marijuana cigarettes. Addict Behav 14:61–67CrossRefPubMedGoogle Scholar
  8. Cocchetto DM, Owens SM, Perez-Reyes M, DiGuiseppi S, Miller LL (1981) Relationship between plasma delta-9-tetrahydrocannabinol concentration and pharmacologic effects in man. Psychopharmacology 75:158–164CrossRefPubMedGoogle Scholar
  9. Compton WM, Grant BF, Colliver JD, Glantz MD, Stinson FS (2004) Prevalence of marijuana use disorders in the United States: 1991–1992 and 2001–2002. JAMA 291:2114–2121CrossRefPubMedGoogle Scholar
  10. Dworkin MS, Williamson JM (2003) AIDS wasting syndrome: trends, influence on opportunistic infections, and survival. J Acquir Immune Defic Syndr 33:267–273PubMedCrossRefGoogle Scholar
  11. ElSohly MA, Feng S, Murphy TP, Ross SA, Nimrod A, Mehmedic Z, Fortner N (1999) Delta 9-tetrahydrocannabivarin (delta 9-THCV) as a marker for the ingestion of cannabis versus Marinol. J Anal Toxicol 23:222–224PubMedGoogle Scholar
  12. Evans SM, Troisi JR II, Griffiths RR (1994) Tandospirone and alprazolam: comparison of behavioral effects and abuse liability in humans. J Pharmacol Exp Ther 271:683–694PubMedGoogle Scholar
  13. Evans SM, Haney M, Levin FR, Foltin RW, Fischman MW (1998) Mood and performance changes in women with premenstrual dysphoric disorder: acute effects of alprazolam. Neuropsychopharmacology 19:499–516PubMedCrossRefGoogle Scholar
  14. Foltin RW, Brady JV, Fischman MW (1986) Behavioral analysis of marijuana effects on food intake in humans. Pharmacol Biochem Behav 25:577–582CrossRefPubMedGoogle Scholar
  15. Foltin RW, Brady JV, Fischman MW, Emurian CS, Dominitz J (1987) Effects of smoked marijuana on social interaction in small groups. Drug Alcohol Depend 20:87–93CrossRefPubMedGoogle Scholar
  16. Foltin RW, Fischman MW, Byrne MF (1988) Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite 11:1–14CrossRefPubMedGoogle Scholar
  17. Foltin RW, Haney M, Comer SD, Fischman MW (1996) Effect of fluoxetine on food intake of humans living in a residential laboratory. Appetite 27:165–181CrossRefPubMedGoogle Scholar
  18. Grinspoon L, Bakalar J (1993) Marihuana, the forbidden medicine. Yale University Press, New HavenGoogle Scholar
  19. Hall W, Degenhardt L (2003) Medical marijuana initiatives: are they justified? How successful are they likely to be? CNS Drugs 17:689–697PubMedCrossRefGoogle Scholar
  20. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW (1999a) Abstinence symptoms following oral THC administration to humans. Psychopharmacology 141:385–394CrossRefPubMedGoogle Scholar
  21. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW (1999b) Abstinence symptoms following smoked marijuana in humans. Psychopharmacology 141:395–404CrossRefPubMedGoogle Scholar
  22. Haney M, Bisaga A, Foltin RW (2003) Interaction between naltrexone and oral THC in heavy marijuana smokers. Psychopharmacology 166:77–85PubMedGoogle Scholar
  23. Haney M, Hart CL, Vosburg SK, Nasser J, Bennett A, Zubaran C, Foltin RW (2004) Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 29:158–170CrossRefPubMedGoogle Scholar
  24. Hart CL, van Gorp W, Haney M, Foltin RW, Fischman MW (2001) Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology 25:757–765CrossRefPubMedGoogle Scholar
  25. Hart CL, Haney M, Ward AS, Fischman MW, Foltin RW (2002a) Effects of oral THC maintenance on smoked marijuana self-administration. Drug Alcohol Depend 67:301–309CrossRefPubMedGoogle Scholar
  26. Hart CL, Ward AS, Haney M, Comer SD, Foltin RW, Fischman MW (2002b) Comparison of smoked marijuana and oral Δ9-THC in humans. Psychopharmacology 164:407–415CrossRefPubMedGoogle Scholar
  27. Heatherington M, Rolls BJ (1987) Methods of investigating human eating behavior. In: Toates F, Rowland N (eds) Feeding and drinking. Elsevier, Amsterdam, pp 77–109Google Scholar
  28. Institute of Medicine (1999) Marijuana and medicine: assessing the science base. National Academy Press, Washington, DCGoogle Scholar
  29. Kirk JM, De Wit H (1999) Responses to oral Δ9-tetrahydrocannabinol in frequent and infrequent marijuana users. Pharmacol Biochem Behav 63:137–142CrossRefPubMedGoogle Scholar
  30. Kosel BW, Aweeka FT, Benowitz NL, Shade SB, Hilton JF, Lizak PS, Abrams DI (2002) The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS 16:543–550CrossRefPubMedGoogle Scholar
  31. Kotler DP, Burastero S, Wang J, Pierson RN (1996) Prediction of body cell mass, fat-free mass, and total body water with bioelectrical impedance analysis: effects of race, sex, and disease. Am J Clin Nutr 64:489S–497SPubMedGoogle Scholar
  32. Martin BR (2002) Medical marijuana—moving beyond the smoke. Lancet 360:4–5CrossRefPubMedGoogle Scholar
  33. Mason AP, McBay AJ (1985) Cannabis: pharmacology and interpretation of effects. J Forensic Sci 30:615–631PubMedGoogle Scholar
  34. Mattes RD, Engelman K, Shaw LM, Elsohly MA (1994) Cannabinoids and appetite stimulation. Pharmacol Biochem Behav 49:187–195PubMedCrossRefGoogle Scholar
  35. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New Engl J Med 338:853–860CrossRefPubMedGoogle Scholar
  36. Palenicek JP, Graham NMH, He YD, Hoover DA, Oishi JS, Kingsley L, Saah AJ (1995) Weight loss prior to clinical AIDS as a predictor of survival. Multicenter AIDS Cohort Study Investigators. J Acquir Immune Defic Syndr 10:366–373Google Scholar
  37. Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG (1991) Recent clinical experience with dronabinol. Pharmacol Biochem Behav 40:695–700CrossRefPubMedGoogle Scholar
  38. Polen MR, Sidney S, Tekawa IS, Sadler M, Friedman GD (1993) Health care use by frequent marijuana smokers who do not smoke tobacco. Western J Med 158:596–601Google Scholar
  39. Pope HG, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D (2001) Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 58:909–915CrossRefPubMedGoogle Scholar
  40. Prentiss D, Power R, Balmas G, Tzuang G, Israelski DM (2004) Patterns of marijuana use among patients with HIV/AIDS followed in a public health care setting. J Acquir Immune Defic Syndr 35:38–45PubMedCrossRefGoogle Scholar
  41. Robson P (2001) Therapeutic aspects of cannabis and cannabinoids. Br J Psychol 178:107–115CrossRefGoogle Scholar
  42. Struwe M, Kaempfer SH, Geiger CJ, Pavia AT, Plasse TF, Shepard KV, Ries K, Evans TG (1993) Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother 27:827–831PubMedGoogle Scholar
  43. Tashkin DP (1999) Marihuana and the lung. In: Nahas GG, Pace N, Cancro R (eds) Marihuana and medicine. Humana Press, Totowa, NJ, pp 279–287Google Scholar
  44. Timpone JG, Wright DJ, Li N, Egorin MJ, Enama ME, Mayers J, Galetto G (1997) The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronobinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative. AIDS Res Hum Retroviruses 13:305–315PubMedCrossRefGoogle Scholar
  45. Wu T, Tashkin DP, Djahed B, Rose JE (1988) Pulmonary hazards of smoking marijuana as compared with tobacco. New Engl J Med 318:347–351PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Margaret Haney
    • 1
  • Judith Rabkin
    • 1
  • Erik Gunderson
    • 1
  • Richard W. Foltin
    • 1
  1. 1.New York State Psychiatric InstituteCollege of Physicians and Surgeons of Columbia UniversityNew YorkUSA

Personalised recommendations